Compare DKI & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DKI | ADVB |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | Hong Kong | United States |
| Employees | 19 | 31 |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1M | 10.1M |
| IPO Year | N/A | N/A |
| Metric | DKI | ADVB |
|---|---|---|
| Price | $4.80 | $4.49 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 76.1K | 30.4K |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.26 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.28 | $0.19 |
| 52 Week High | $11.80 | $7.70 |
| Indicator | DKI | ADVB |
|---|---|---|
| Relative Strength Index (RSI) | 47.50 | 49.10 |
| Support Level | $0.39 | $4.50 |
| Resistance Level | $6.80 | $5.83 |
| Average True Range (ATR) | 0.80 | 0.45 |
| MACD | -0.22 | 0.09 |
| Stochastic Oscillator | 16.15 | 59.01 |
Darkiris Inc is a comprehensive technology enterprise engaged in the development, publishing and operating of mobile digital games via various third-party digital storefronts. Its activities encompass including game design, programming and graphics, as well as distribution and operation of mobile games on various platforms. Its core product offerings are Games Development; develop, market and distribute its self-developed mobile games; and Games Publishing and Operation. It publish and operate its self-developed mobile games and mobile games it license from other game developers.
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.